<div id="readability-page-1"><ul><li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li></ul><p>AbCellera Biologics <span>NASDAQ: ABCL<span></span></span> is shifting from a partnership-driven discovery business toward advancing its own internally developed clinical pipeline, Chief Financial Officer Andrew Booth said during a company presentation. Booth highlighted the company’s cash position, expanded end-to-end capabilities—including GMP manufacturing—and the near-term focus on a Phase II readout for its lead program ABCL635 in menopausal hot flashes.</p><div><p><span></span><span>Get <strong>AbCellera Biologics</strong> alerts:</span></p></div><h2>From partnership model to internal pipeline</h2> <p>Booth said AbCellera was spun out of University of British Columbia professor Carl Hansen’s lab, with Hansen serving as founding CEO. In its first eight years, the company focused on “rebuilding the front end of drug discovery” for therapeutic antibodies using newer technologies. AbCellera then took those capabilities to market in a partnership model, working with large pharmaceutical companies and biotechs on partner-chosen targets, while retaining downstream economics through milestones and royalties. </p><p>Booth described the approach as capital efficient, noting the company “managed to not raise very much money at all” during that period. He added that partners typically brought AbCellera “very, very hard stuff,” citing major pharmaceutical companies that relied on AbCellera’s technical angles for difficult discovery problems.  </p><h2>COVID antibodies, cash position, and expanded capabilities</h2> <p>Booth said that around 2020 the company completed its first significant private raise and served as the discovery engine behind Eli Lilly’s COVID-19 antibodies, which he said went to about 2.5 million patients and were estimated to have saved “tens of thousands of lives.” He said AbCellera’s royalty on those products “filled up our balance sheet with probably about $1 billion worth of cash,” alongside proceeds from the company’s IPO and Canadian government support. </p><p>According to Booth, that funding helped AbCellera build capabilities across the development chain, including target work, discovery, development, translational sciences, process development, cell line development, and GMP manufacturing. He said the company now has its own GMP facility and expects to manufacture its therapeutic antibodies internally going forward. </p><p>While the partnership business has included more than 100 antibody programs, Booth said the company’s downstream participation portfolio remains difficult for the market to value because it is still early-stage. He noted there are “16 or 17 molecules” in the clinic where AbCellera has downstream participation, but said he believes the market assigns “precisely zero value” to that portfolio today because few partnered programs have reached late-stage development.  </p><h2>Pipeline focus: difficult targets and clinical cadence</h2> <p>Booth said AbCellera is focused on difficult-to-drug targets such as ion channels and GPCRs, arguing these complex membrane proteins represent a competitive differentiation because it can be challenging to find antibodies that bind them. He also cited multi-specific capabilities and “next generation ADCs,” and emphasized the company is “indication agnostic,” selecting targets where its technology can address the underlying problem rather than limiting itself to a single therapeutic area. </p><p>He said AbCellera has more than 20 programs in discovery and sizes its portfolio to advance “about one-two programs a year” into the clinic, depending on scientific conviction. Booth added that the company now has two clinical programs in the clinic and two more expected to enter the clinic “sometime in next year or about a year from now.” He also referenced “about $700 million in available liquidity,” which he said provides capital to continue advancing the pipeline.  </p><h2>Lead program ABCL635: Phase II data expected in Q3</h2> <p>Booth spent much of the presentation on ABCL635, which he described as a first-in-class antibody targeting the neurokinin 3 receptor (NK3R), a GPCR implicated in menopausal hot flashes. He said the target has been validated by two approved small-molecule drugs: Astellas’ fezolinetant and Bayer’s elinzanetant. However, he framed a key scientific question for ABCL635 as whether an antibody can effectively engage the target in the relevant brain region. </p><p>Booth outlined AbCellera’s commercial rationale, stating the company estimates about 12 million U.S. women experience moderate-to-severe hot flashes at any point in time, with symptoms lasting seven to 10 years. He said about half seek treatment, and that contraindications or tolerability issues for hormone replacement therapy encompass roughly 20% of those patients—about 1.2 million women. Using an estimated $5,000 annual net price for non-hormonal options, he pegged the total addressable market at roughly $6 billion. </p><p>He also pointed to safety considerations with existing small molecules, including liver monitoring requirements and, in the case of fezolinetant, a boxed warning. Booth said Astellas reached about $300 million in its second year of sales despite those requirements, and he cited the company’s peak sales expectations of $1 billion to $1.7 billion, with similar expectations referenced for Bayer’s product. </p><p>AbCellera’s target product profile for ABCL635 includes a once-monthly subcutaneous injection delivered by autoinjector, with a “clean safety signal” and no somnolence. Booth said elinzanetant’s dual NK1R/NK3R activity is associated with somnolence and that the company does not expect either liver toxicity or somnolence with a monoclonal antibody. He also cited a patient survey in which more than half of respondents preferred a monthly self-administered injection over a daily oral option if efficacy and safety were the same; among those with autoinjector experience, the preference rose above 75%. </p><p>Booth said AbCellera plans to disclose ABCL635 preclinical and Phase I data—including safety and PK/PD—at its May 11 earnings call, after previously intending to release preclinical, Phase I, and Phase II data together. He described the Phase II trial as a double-blind, placebo-controlled study in about 80 patients with moderate-to-severe hot flashes, measuring frequency and severity endpoints that he said are registrational. Booth said the Phase I and Phase II trials are being run exclusively in Canada, which he described as a first, and tied the effort to work with the governments of Canada and British Columbia. </p><p>During Q&amp;A, Booth said the mechanism behind liver toxicity observed with the small molecules is believed to be related to hepatic metabolism and “not believed to be an on-target effect.” He said AbCellera will closely monitor potential liver toxicity and that the company “feel[s] very good about the safety signal” seen in Phase I, with data to be provided May 11.  </p><h2>Other programs and next steps</h2> <p>Booth briefly discussed ABCL575, an OX40 ligand program he said is similar to Sanofi’s amlitelimab. He noted Sanofi has had a “somewhat disappointing readout” with safety signals and said AbCellera’s intent is to complete Phase I and evaluate partnering opportunities, but the company does not currently intend to advance ABCL575 into Phase II. </p><p>Looking ahead, Booth said that if ABCL635 is successful, AbCellera would pursue additional hot flash indications related to cancer treatment, including breast and prostate cancer patients receiving androgen deprivation therapy. He also cited ABCL688 (autoimmunity) and ABCL386 (oncology) as in IND-enabling studies, with an intent to bring them into the clinic in 2027, along with another program as a “stretch goal.” Booth added that if ABCL635 performs well, AbCellera would aim to move quickly into a registrational trial starting in 2027. </p><p>Asked about the possibility of a head-to-head pivotal trial versus competitors, Booth said the company has considered it but has not made decisions, and will wait for Phase II efficacy results and biomarker data. He described biomarker work from Phase I—testosterone reduction in males as a measure of pathway inhibition—as supportive of target engagement, while emphasizing that the remaining unknown is whether that translates into reduced hot flash frequency and severity. Booth also noted a remaining scientific risk: NK3R is expressed in the preoptic nucleus, which small molecules may reach, but the antibody is not expected to reach—something he said the Phase II trial should help address.</p><h2>About AbCellera Biologics <span>NASDAQ: ABCL<span></span></span></h2><p>AbCellera Biologics Inc <span>NASDAQ: ABCL<span></span></span> is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.  </p><p>AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.</p><h2>Read More</h2><ul><li>Five stocks we like better than AbCellera Biologics</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbCellera Biologics Right Now?</h2><p>Before you consider AbCellera Biologics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.</p><p>While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABCL

LABU

SBIO

<p>AbCellera Biologics (NASDAQ:ABCL) is transitioning from a partnership-driven model to focus on its own clinical pipeline, as stated by CFO Andrew Booth. The company has developed expanded capabilities, including GMP manufacturing, and is set to release Phase II data for its lead program ABCL635, targeting menopausal hot flashes. With over $700 million in liquidity, AbCellera aims to advance one to two programs annually, emphasizing difficult drug targets. The total addressable market for ABCL635 is estimated at $6 billion, with significant potential for growth in the treatment of hot flashes.</p>

Market Beat

Abcellera Biologics

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Argenx

Eli Lilly

Astellas Pharma Inc.

Astellas Pharma

Bayer AG

Bayer

Bayer Aktiengesellschaft

AbCellera Biologics Pivots to In-House Pipeline, Teases Q3 Phase II Data for ABCL635 Hot Flashes